Love Your Hair Color? You Have 100 Genes to Thank

The researchers who pinpointed the origins of hair hue said their findings could improve understanding of health conditions linked to pigmentation, including skin, testicular, prostate and ovarian cancers.
Source: WebMD Health - Category: Consumer Health News Source Type: news

Related Links:

atankar Aerobic glycolysis is an important metabolic adaptation of cancer cells. There is growing evidence that oxidative phosphorylation is also an active metabolic pathway in many tumors, including in high grade serous ovarian cancer. Metastasized ovarian tumors use fatty acids for their energy needs. There is also evidence of ovarian cancer stem cells privileging oxidative phosphorylation (OXPHOS) for their metabolic needs. Metformin and thiazolidinediones such as rosiglitazone restrict tumor growth by inhibiting specific steps in the mitochondrial electron transport chain. These observations suggest that strategies...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Could it make surgery smarter? Related items fromOnMedica Cancer patients using complementary meds die sooner NICE updates lung cancer guidance Sentinel node biopsy first to check spread of oral cancer Surgeons forced to lie about their hours Cancer strategies failed to improve one-year survival
Source: OnMedica Blogs - Category: General Medicine Source Type: blogs
Opinion statementLow-grade serous ovarian cancer (LGSOC) is a rare subtype of ovarian cancer, accounting for approximately 10% of cases of serous ovarian cancer. Patients typically present at a younger age have a protracted clinical course with survival for those with recurrent disease nearing 10  years, and have a high prevalence of somatic (tumor-specific) mutations affecting the mitogen-activated protein kinase (MAPK) pathway. Initial treatment of patients with stage IC–IV disease is similar to that of high-grade serous ovarian cancer with surgery and platinum/taxane-based chemotherapy . Selected patients may...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Certain malignancies may possess a common and targetable matrix response, which affects disease pathogeneis, according to a study inCancer Discovery.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
CONCLUSION: The data collected during our study highlight the unprecedented place that could be that of the general practitioner in the field of prevention in genetics. At the articulation between primary care and highly specialized care, it is the figure of the "family" doctor who seems to be called here to be renewed by genetics. PMID: 30219572 [PubMed - as supplied by publisher]
Source: Revue d Epidemiologie et de Sante Publique - Category: Epidemiology Tags: Rev Epidemiol Sante Publique Source Type: research
Standard-of-care treatment for patients with pleural mesothelioma may soon include Tumor Treating Fields (TTF), a novel therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth. In the wake of recently released results from Novocure’s STELLAR phase II clinical trial, the U.S. Food and Drug Administration (FDA) is expected to approve the treatment within the next six months, giving mesothelioma patients another much-needed option. “At this point, it should be a relatively rapid approval process,” Dr. Eilon Kirson, chief science officer at Novocure, the oncology company...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conditions:   Cancer;   Hematologic Disorder;   Infertility;   Ovarian Failure Intervention:   Other: Ovarian Cryopreservation Sponsor:   St. Justine's Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Low Grade Serous Carcinoma Interventions:   Drug: Ribociclib;   Drug: Letrozole Sponsors:   Gynecologic Oncology Group;   Novartis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Cancer;   Hematologic Disorder;   Infertility;   Ovarian Failure Intervention:   Other: Ovarian Cryopreservation Sponsor:   St. Justine's Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Genetics | Health | Ovarian Cancer | Ovaries | Skin